Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland…
Elasmogen wins two grants worth £374,000
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK,…
Elasmogen announces grants of 2 new VNAR and soloMER patent families
New grants across multiple territories cover the use of humanised or de-immunised VNARs for…
Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both…
Elasmogen Researcher receives prestigious £2m fellowship to help establish him as future UK bioscience leader
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been…
Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland…
Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge
Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen,…
Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight
Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of…
Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting
Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on…
Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of…
Elasmogen CEO shortlisted for BBSRC Innovator of the Year 2019 award
Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the…
Elasmogen CEO Caroline Barelle named one of top 20 women in leading biotech roles in Europe
Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May…